BioCentury
ARTICLE | Clinical News

Lynparza olaparib: Phase III data

October 31, 2016 7:00 AM UTC

Top-line data from the double-blind, international Phase III SOLO-2 trial in 295 patients with platinum-sensitive, relapsed or recurrent BRCA-mutant ovarian cancer showed that maintenance treatment wi...